Phase I trial of combination chemotherapy with gemcitabine, cisplatin, and S-1 in patients with advanced biliary tract cancer | Zendy

Akinori Watanabe | Zendy; Mitsuhiro Kida | Zendy; Shiro Miyazawa | Zendy; Tomohisa Iwai | Zendy; Kosuke Okuwaki | Zendy; Toru Kaneko | Zendy; Hiroshi Yamauchi | Zendy; Miyoko Takezawa | Zendy; Hiroshi Imaizumi | Zendy; Wasaburo Koizumi | Zendy

Open Access

Phase I trial of combination chemotherapy with gemcitabine, cisplatin, and S-1 in patients with advanced biliary tract cancer

Author(s) -

Akinori Watanabe,

Mitsuhiro Kida,

Shiro Miyazawa,

Tomohisa Iwai,

Kosuke Okuwaki,

Toru Kaneko,

Hiroshi Yamauchi,

Miyoko Takezawa,

Hiroshi Imaizumi,

Wasaburo Koizumi

Publication year - 2015

Publication title -

world journal of gastroenterology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.427

H-Index - 155

eISSN - 2219-2840

pISSN - 1007-9327

DOI - 10.3748/wjg.v21.i19.5979

Subject(s) - gemcitabine , medicine , neutropenia , cisplatin , chemotherapy , febrile neutropenia , gastroenterology , biliary tract cancer , cancer , tegafur , phases of clinical research , deoxycytidine , biliary tract

To evaluate the dose-limiting toxicities (DLTs) and determine the maximum-tolerated dose (MTD) and recommended dose (RD) of combination chemotherapy with gemcitabine, cisplatin and S-1 which is an oral fluoropyrimidine pro-drug in patients with advanced biliary tract cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research